Abstract
Objective To evaluate the safety of bevacizumab combined with platinum-based thoracic perfusion for treating lung cancer-related malignant pleural effusion (MPE) through meta-analysis. Methods The CNKI, PubMed, Cochrane Library, Embase, Chinese Science and Technology Journal Database (VIP), and Wanfang Databases were searched for randomized controlled trials (RCTs) of bevacizumab combined with platinum-based thoracic perfusion for the treatment of MPE. The references included in the articles were manually searched for additional studies. A meta-analysis of the RCTs was conducted using the RevMan 5.3 application. Results A total of 8 studies involving 540 patients (271 cases in the test group and 269 cases in the control group) were included in the meta-analysis. The test group had a significantly greater risk of elevated blood pressure as well as a higher rate of complete remission (CR) compared to the control group (P < 0.05). In contrast, the incidence of partial remission (PR) was only slightly higher in the test group (P > 0.05), and the risks of leukopenia, vomiting or nausea, rhinorrhea, diarrhea, gastrointestinal bleeding or hemoptysis, proteinuria, abnormal kidney and liver function, arrhythmia, and rashes were not significantly different between the test and control groups (P > 0.05). Conclusion Bevacizumab combined with platinum-based thoracic perfusion can achieve CR of MPE in patients with advanced lung cancer without significantly increasing the risk of adverse effects. The rate of PR was similar for the combination treatment and platinum-based infusion.
Highlights
To evaluate the safety of bevacizumab combined with platinum-based thoracic perfusion for treating lung cancerrelated malignant pleural effusion (MPE) through meta-analysis
Bevacizumab combined with platinum-based thoracic perfusion can achieve complete remission (CR) of MPE in patients with advanced lung cancer without significantly increasing the risk of adverse effects. e rate of partial remission (PR) was similar for the combination treatment and platinum-based infusion
Five studies reported the frequency of nasal bleeding, hemoptysis, or gastrointestinal bleeding among 134 patients in the trial group and 132 patients in the control
Summary
To evaluate the safety of bevacizumab combined with platinum-based thoracic perfusion for treating lung cancerrelated malignant pleural effusion (MPE) through meta-analysis. A total of 8 studies involving 540 patients (271 cases in the test group and 269 cases in the control group) were included in the meta-analysis. Bevacizumab combined with platinum-based thoracic perfusion can achieve CR of MPE in patients with advanced lung cancer without significantly increasing the risk of adverse effects. Combined intrathoracic perfusion therapy is an effective treatment modality for MPE, and several studies have reported better outcomes and lower drug toxicity with this approach.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
